The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database Analysis

NCT03026556 · clinicaltrials.gov ↗

COMPLETED

Status

42534

Enrollment

INDUSTRY

Sponsor class

Conditions

Atrial Fibrillation

Interventions

DRUG: Dabigatran vs. Rivaroxaban
DRUG: Dabigatran vs. Apixaban

Sponsor

Boehringer Ingelheim

Collaborators

[object Object]
[object Object]
[object Object]